Abstract:
Objective To investigate the effect of low-dose paclitaxel combined with thalidomide on angiogenesis in mice bearing S180 sarcoma.
Methods An S180 sarcoma-bearing mouse model was established. Forty tumor-bearing mice were randomly divided into four groups:A, the control group, administered normal saline; B, the paclitaxel group, administered 20 mg/kg paclitaxel by intraperitoneal injection three times per week for 2 weeks; C, the thalidomide group, administered 200 mg/kg thalidomide by gavage three times per week for 2 weeks; and D, the paclitaxel + thalidomide group, administered paclitaxel (20 mg/kg) and thalidomide (200 mg/kg) by intraperitoneal/intragastric administration three times per week for 2 weeks. Tumor weight, tumor inhibition rate, microvascular density (MVD), and vascular endothelial growth factor (VEGF) expression were measured.
Results Tumor weight, VEGF expression, and MVD were lower in groups B, C, and D (P < 0.05) than in the control. VEGF expression and MVD were lower in group D than in groups B and C; these differences were statistically significant (P < 0.05).
Conclusions Low-dose paclitaxel combined with thalidomide exerted an inhibitory effect on vascular growth in S180 sarcoma.